Gates Foundation Strategic Investment Fund Logo
Share this page:

The New York Times: From the Gates Foundation, direct investment, not just grants

By Sarah Max

March 12, 2015

The Ebola crisis underscored a problem that vexes experts in global health: Vaccines are one of the most cost-effective ways to save lives, especially in developing countries, yet traditional vaccines can take years to develop.

So when the Bill & Melinda Gates Foundation came across CureVac, a biopharmaceutical company working on technology that could produce vaccines faster, cheaper and more effectively, it not only took note — it took a stake in the company.

Read the full text here.